Destro M, Cagnoni F, Dognini GP, Galimberti V, Taietti C, Cavalleri C, et al. Telmisartan: just an antihypertensive agent? A literature review. Expert Opin Pharmacother. 2011;12(17):2719–35. https://doi.org/10.1517/14656566.2011.632367.

Article  CAS  PubMed  Google Scholar 

Plosker GL, White WB. Telmisartan/hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension. Drugs. 2008;68(13):1877–99. https://doi.org/10.2165/00003495-200868130-00010.

Article  CAS  PubMed  Google Scholar 

Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs. 2006;66(15):51–83. https://doi.org/10.2165/00003495-200666010-00004.

Article  CAS  PubMed  Google Scholar 

Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024;171: 116169. https://doi.org/10.1016/j.biopha.2024.116169.

Article  CAS  PubMed  Google Scholar 

Rothlin RP, Pelorosso FG, Duarte M, Nicolosi L, Ignacio FC, Salgado MV, et al. Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19. Pharmacol Res Perspect. 2023;11(2): e01083. https://doi.org/10.1002/prp2.1083.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deppe S, Böger RH, Weiss J, Benndorf RA. Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opin Drug Metab Toxicol. 2010;6(7):863–71. https://doi.org/10.1517/17425255.2010.494597.

Article  CAS  PubMed  Google Scholar 

Romodanovskii D, Goryachev D, Khokhlov A, Miroshnikov A. Investigation planning and bioequivalence evaluation of angiotensin II receptor antagonists. Pharm Chem J. 2019;53:680–4. https://doi.org/10.1007/s11094-019-02062-4.

Article  CAS  Google Scholar 

Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37. https://doi.org/10.1038/s41581-019-0244-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785–802. https://doi.org/10.1038/s41569-021-00559-8.

Article  PubMed  PubMed Central  Google Scholar 

Fagiolino P, Eiraldi R, Vázquez M. The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships. Clin Pharmacokinet. 2006;45(5):433–48. https://doi.org/10.2165/00003088-200645050-00001.

Article  CAS  PubMed  Google Scholar 

Peeters L, Kester M, Feyz L, Van Den Bemt P, Koch B, Van Gelder T, et al. Pharmacokinetic and pharmacodynamic considerations in the treatment of the elderly patient with hypertension. Expert Opin Drug Metab Toxicol. 2019;15(4):287–97. https://doi.org/10.1080/17425255.2019.1588249.

Article  CAS  PubMed  Google Scholar 

Rigby J, Scott A, Hawksworth G, Petrie J. A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects. Br J Clin Pharmacol. 1985;20(4):327–31. https://doi.org/10.1111/j.1365-2125.1985.tb05072.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abernethy DR. An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. Am J Cardiol. 1994;73(3):10A-17A. https://doi.org/10.1016/0002-9149(94)90269-0.

Article  CAS  PubMed  Google Scholar 

Meredith P, Elliott H, McSharry D, Kelman A, Reid J. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. Br J Clin Pharmacol. 1983;16(1):27–32. https://doi.org/10.1111/j.1365-2125.1983.tb02139.x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Landahl S, Edgar B, Gabrielsson M, Larsson M, Lernfelt B, Lundborg P, et al. Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients: a comparison with young healthy subjects. Clin Pharmacokinet. 1988;14(6):374–83. https://doi.org/10.2165/00003088-198814060-00004.

Article  CAS  PubMed  Google Scholar 

Marino MR, Vachharajani NN. Pharmacokinetics of irbesartan are not altered in special populations. J Cardiovasc Pharmacol. 2002;40(1):112–22. https://doi.org/10.1097/00005344-200207000-00014.

Article  CAS  PubMed  Google Scholar 

Holford NH, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet. 1981;6(6):429–53. https://doi.org/10.2165/00003088-198106060-00002.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906. https://doi.org/10.1016/j.ijsu.2021.105906.

Article  PubMed  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.

Article  PubMed  PubMed Central  Google Scholar 

Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting guidelines for clinical pharmacokinetic studies: the ClinPK statement. Clin Pharmacokinet. 2015;54(7):783–95. https://doi.org/10.1007/s40262-015-0236-8.

Article  PubMed  Google Scholar 

Keizer RJ, Karlsson M, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2(6): e50. https://doi.org/10.1038/psp.2013.24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35(2):185–202. https://doi.org/10.1007/s10928-007-9081-1.

Article  PubMed  PubMed Central  Google Scholar 

Baverel PG, Savic RM, Karlsson MO. Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2011;38(1):63–82. https://doi.org/10.1007/s10928-010-9177-x.

Article  PubMed  Google Scholar 

Madhusudhan K, Mahesh K, Balusu N, Kumar M, Savakula S, Reddy SSS, et al. Pharmacokinetic and bioequivalence com-parison between telmisartan tablets 80mg: an open label, balanced, randomized-sequence, single-dose, two-period cross-over study in healthy male volunteers. Int J Pharm Drug Anal. 2016;4(8):403–10.

Google Scholar 

Hirvensalo P, Tornio A, Launiainen T, Paile-Hyvärinen M, Tapaninen T, Neuvonen M, et al. UGT1A3 and sex are major determinants of telmisartan pharmacokinetics—a comprehensive pharmacogenomic study. Clin Pharmacol Ther. 2020;108(4):885–95. https://doi.org/10.1002/cpt.1928.

Article  CAS  PubMed  Google Scholar 

Young CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol. 2000;40(12 Pt 1):1323–30. https://doi.org/10.1177/009127000004001203.

Article  CAS  PubMed  Google Scholar 

Seong SJ, Lim MS, Lee J, Ohk B, Gwon MR, Kim BK, et al. Evaluation of a pharmacokinetic interaction between telmisartan and chlorthalidone in healthy male adult subjects. Clin Drug Investig. 2016;36(8):613–23. https://doi.org/10.1007/s40261-016-0406-y.

Article  CAS  PubMed  Google Scholar 

Kim CH, Kang SI, Shin D. Pharmacokinetic interaction between telmisartan and rosuvastatin/ezetimibe after multiple oral administration in healthy subjects. Adv Ther. 2021;38(2):1094–105. https://doi.org/10.1007/s12325-020-01592-8.